Durata Therapeutics Closes Public Offering of Common Stock
April 17, 2013 16:15 ET
|
Durata Therapeutics, Inc.
CHICAGO, April 17, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) today announced the closing of its public offering of 8,222,500 shares of common stock at a public offering price of...
Durata Therapeutics Prices Public Offering of Common Stock
April 12, 2013 07:30 ET
|
Durata Therapeutics, Inc.
CHICAGO, April 12, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) today announced the pricing of an underwritten public offering of 7,150,000 shares of its common stock at a public...
Durata Therapeutics to Host Reimbursement Seminar on April 23, 2013
April 02, 2013 15:30 ET
|
Durata Therapeutics, Inc.
CHICAGO, April 2, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) today announced that it will host a reimbursement seminar for the investment community on Tuesday, April 23, 2013 at...
Durata Therapeutics, Inc. Reports Full-Year 2012 Financial Results
March 08, 2013 07:00 ET
|
Durata Therapeutics, Inc.
CHICAGO, March 8, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) today announced financial results for the year ended December 31, 2012.
"2012 was a great year for Durata. We...
Durata Therapeutics to Announce Full Year 2012 Financial Results on Friday, March 8, 2013
March 05, 2013 16:30 ET
|
Durata Therapeutics, Inc.
CHICAGO, March 5, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics (Nasdaq:DRTX) has scheduled its quarterly conference call for Friday, March 8, 2013 at 8:30 a.m. Eastern Time to discuss full year 2012...
Durata Therapeutics Announces Preliminary, Topline Phase 3 Clinical Trial Results for Dalbavancin in the Treatment of ABSSSI
February 25, 2013 07:00 ET
|
Durata Therapeutics, Inc.
DISCOVER 2 Study Meets Primary & Secondary Endpoints
Conference Call and Webcast Today at 8:30 A.M. EST to Discuss Results
CHICAGO, Feb. 25, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics,...
Durata Therapeutics to Present at the Cowen & Company 33rd Annual Health Care Conference
February 20, 2013 14:00 ET
|
Durata Therapeutics, Inc.
CHICAGO, Feb. 20, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics (Nasdaq:DRTX) today announced that Durata's Chief Executive Officer Paul R. Edick will present an overview of the company at the Cowen...
Durata Therapeutics to Present at the 2013 RBC Capital Markets' Global Healthcare Conference
February 13, 2013 16:00 ET
|
Durata Therapeutics, Inc.
CHICAGO, Feb. 13, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics (Nasdaq:DRTX) today announced the company will participate in the RBC Capital Markets' Global Healthcare Conference scheduled for...
Durata Therapeutics Meets Primary Endpoints for EMA Review in Phase 3 Clinical Trial
January 04, 2013 08:30 ET
|
Durata Therapeutics, Inc.
CHICAGO, Jan. 4, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) today announced additional preliminary, top-line results for its DISCOVER 1 ("Dalbavancin for Infections of the Skin...